Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in primary immune thrombocytopenia
NCT05124028Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of orelabrutinib in immune thrombocytopenia (ITP), sponsored by Peking University People's Hospital. Primary endpoint: Overall response at 6 weeks. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05124028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124028.